Chiung-Tong Chen

USPTO Granted Patents = 15 (Patent Applications = 5)

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

Zhunan, TW (2011 - 2016)
Taipei, TW (2005 - 2020)
Miaoli County, TW (2018 - 2024)

Company Filing History:

15 out of 181

National Health Research Institutes

patents

1 out of 96

Development Center for Biotechnology

Molecular Targeting Technologies. Inc.

patents

where one patent can have more than one assignee

Years Active: 2005-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12091454 - Humanized anti-human neurotensin receptor 1 antibodies and their uses (2024-09-17),

2. 11878986 - Poly heterocyclic conjugates and their pharmaceutical uses (2024-01-23),

3. 10584120 - Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease (2020-03-10),

4. 9926298 - Heterocyclic compounds and use thereof (2018-03-27),

5. 9862703 - Heterocyclic compounds and use thereof (2018-01-09),

6. 9388193 - Dipicolylamine derivatives and their pharmaceutical uses (2016-07-12),

7. 8026271 - Formulations of indol-3-yl-2-oxoacetamide compounds (2011-09-27),

8. 7662834 - Methods of 1H-indol-3-yl-2-oxoacetamide compounds (2010-02-16),

9. 7569596 - Imidazolamino compounds (2009-08-04),

10. 7501445 - Imidazolidinone compounds (2009-03-10),

11. 7462723 - Imidazolamino compounds (2008-12-09),

12. 7396838 - Use of 1H-indol-3-yl-2-oxoacetamide compounds (2008-07-08),

13. 7129359 - Imidazolidinone compounds (2006-10-31),

14. 7109227 - Imidazolamino compounds (2006-09-19),

15. 6903104 - Indol-3-YL-2-oxoacetamide compounds and methods of use thereof (2005-06-07),

Title: The Innovations of Chiung-Tong Chen

Introduction

Chiung-Tong Chen is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies and pharmaceutical compounds. With a total of 15 patents to his name, Chen's work has had a substantial impact on medical research and treatment methodologies.

Latest Patents

Among his latest patents is the development of humanized anti-human neurotensin receptor 1 antibodies and their uses. This patent includes a humanized anti-neurotensin receptor 1 (NTSR1) antibody or an antigen-binding fragment thereof. It also outlines a method for treating, prophylactic treating, and/or preventing diseases and/or disorders caused by or related to NTSR1 activity and/or signaling, as well as a method or kit for detecting NTSR1 in a sample. Another notable patent involves poly heterocyclic conjugates and their pharmaceutical uses, which details compounds of Formula (I) and a pharmaceutical composition containing one of these compounds. This patent also discloses a method of treating conditions associated with uncontrolled cell growth using a compound of Formula (I).

Career Highlights

Chiung-Tong Chen has worked with esteemed organizations such as the National Health Research Institutes and the Development Center for Biotechnology. His career has been marked by a commitment to advancing medical science through innovative research and development.

Collaborations

Throughout his career, Chen has collaborated with notable colleagues, including Der-Ren Hwang and Wen-Tai Li. These partnerships have further enhanced the scope and impact of his research.

Conclusion

Chiung-Tong Chen's contributions to biotechnology and his extensive patent portfolio underscore his role as a leading inventor in the field. His innovative work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.